Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 2 de 2
Add filters

Year range
2022 IEEE International Conference on Bioinformatics and Biomedicine, BIBM 2022 ; : 795-798, 2022.
Article in English | Scopus | ID: covidwho-2235051


Rapid development and distribution of vaccines have been a hallmark of the battle against COVID-19. While the efficacy, clinical trials, adverse health effects, and sociodemographic and clinical factors determining the distribution of vaccines have been studied extensively, there has been little effort to design cost-effective vaccine provisioning schemes. We introduce a vaccine provisioning scheme that leverages coalitional game theory to improve the cost of vaccines while meeting the epidemiological demand of neighboring zones. The proposed approach incentivizes bulk purchases by groups (or coalitions) of zones at lower prices while penalizing large coalitions to avoid logistical challenges. Moreover, it enables the policymaker to model the vaccine demand of zones based on their epidemiological profiles, such as susceptible, infected numbers or population density, or a combination thereof. We carry out experiments using the SEIRD (susceptible, exposed, infected, recovered, death) epidemic model as well as the daily confirmed cases in the five boroughs of New York City to show the efficacy of the approach. © 2022 IEEE.

NTIS; 2020.
Non-conventional in English | NTIS | ID: grc-753746


The overall goal of this award is to find ways to prolong the efficacy of cabazitaxel chemotherapy in patients with castration resistant prostate cancer (CRPC) who have previously been treated with and developed resistance to Abiraterone Acetate (ABI) or enzalutamide (ENZ). In months 1-12 of this award, we aimed to determine whether a novel galectin-1 (Gal-1) inhibitor, S-LLS30 developed by the applicant, prevents ABI/ENZ resistance and/or sensitizes the cells to cabazitaxel (Major task 1). We have shown that indeed S-LLS30 sensitizes CRPC cells to ENZ and strongly affected cells expressing Gal-1. The experiments with cabazitaxel are continuing despite prolonged operational shutdown at the University due to COVID-19 restrictions. We have also started to investigate the role of Gal-1 nuclear localization, and its binding partners Gemin4 and HSP90 in this process (Major task 2, subtask 1). It appears that Gemin4 plays a substantial role in Gal-1 activity in this context but the role of HSP90 is unclear. Finally, we conducted preliminary experiments to evaluate the toxicity of S-LLS30 and determine the maximum tolerated dose (Major task 3, subtask 1). S-LLS30 was deemed to be of limited toxicity and very well tolerated in mice up to 30 mg/Kg doses. S-LLS30 is a viable potential drug candidate to overcome resistance to ABI/ENZ in models of CRPC.